Table 1.
Country | Definition (yr) | The content of definition |
---|---|---|
Japan | Original (2016) | (1) Patients have a history of treatment with BP or Dmab; (2) Patients have no history of radiation therapy to the jaw. Bone lesions of ARONJ must be differentiated from cancer metastasis to the jawbone by histological examination; (3) Exposure of alveolar bone in the oral cavity, jaw, and/or face is continuously observed for longer than 8 weeks after first detection by a medical or dental expert, or the bone is palpable in the intra- or extraoral fistula for longer than 8 weeks. These criteria do not apply to stage 0 ARONJ. |
Korea | AAOMS position paper (2014) | (1) Current or previous treatment with antiresorptive or antiangiogenic agents; (2) Exposed bone or bone that can be probed through an intraoral or extraoral fistula in the maxillofacial region that has persisted for longer than 8 weeks; (3) No history of radiation therapy to the jaws or obvious metastatic disease to the jaws. |
Hong Kong | ASBMR (2007) and AAOMS position paper (2009) | ASBMR: BRONJ was defined as an area of exposed bone in the maxillofacial region that did not heal within 8 week after identification by a health care provider, in a patient who was receiving or had been exposed to a BPs and had not had radiation therapy to the craniofacial region. AAOMS: (1) Current or previous treatment with a BP; (2) Exposed bone in the maxillofacial region that has persisted for more than 8 weeks; (3) No history of radiation therapy to the jaws. |
Taiwan Singapore India Jordan |
AAOMS position paper (2009) | (as defined above) |
ONJ, osteonecrosis of the jaw; BP, bisphosphonate; Dmab, denosumab; ARONJ, antiresorptive agent-related osteonecrosis of the jaw; AAOMS, American Association of Oral and Maxillofacial Surgeons; ASBMR, American Society for Bone and Mineral Research.